Intensive Tobacco Treatment for Smoking Cessation in Cancer Patients

Overseen By Kayla Fay

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Dartmouth-Hitchcock Medical Center

Disqualifiers: Unable to consent, prisoners

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 3

2 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to assess the cessation success rates of an intensive tobacco treatment program in a patients undergoing cancer treatment at 30 days, 3 months and 6 months.

Who Is on the Research Team?

Joseph D Phillips, MD

Principal Investigator

Dartmouth-Hitchcock Medical Center

Are You a Good Fit for This Trial?

This trial is for adults aged 18 or older who are actively smoking at the time of their initial cancer consultation, which means they've smoked within the last two weeks. It's not open to those unable to consent or prisoners.

Inclusion Criteria

You have been smoking within the past two weeks before your consultation for cancer.

Exclusion Criteria

Prisoners

I am unable to give consent for medical procedures.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intensive Tobacco Treatment

Participants receive intensive tobacco treatment with carbon monoxide monitoring, including counseling and pharmacotherapy as needed

6 months

Initial in-person visit, then biweekly via telephone or telehealth

Follow-up

Participants are monitored for cessation success rates at 30 days, 3 months, and 6 months

6 months

3 additional survey time points

What Are the Treatments Tested in This Trial?

Interventions

• Intensive Tobacco Treatment

Trial Overview The CORE study is testing how well an intensive tobacco treatment program helps cancer patients quit smoking. Success rates will be checked after 30 days, and then again at 3 and 6 months into the treatment.

How Is the Trial Designed?

Group I: Intensive Tobacco Treatment Experimental Treatment 1 Intervention

Patients who consent to study participation will meet with a tobacco treatment specialist in-person initially, then biweekly via telephone or telehealth or face-to-face (or more frequently as needed). They will receive tobacco treatment counseling and support from certified tobacco treatment specialist, which may include pharmacotherapy as indicated. At enrollment, participants will undergo carbon monoxide testing using a carbon monoxide monitor. At baseline, participants will complete the Fagerström Test for Nicotine Dependence, and the Cancer Patient Tobacco Use Questionnaire (C-TUQ). These tobacco related survey measures will be completed at 3 additional time points: 30 days, 3 months and 6 months.

Group II: Usual Tobacco Treatment Active Control 1 Intervention

All individuals who are identified as tobacco users are offered tobacco treatment which includes proactive, as needed, contacts via in person, telehealth or telephone visits. for tobacco treatment, pharmacotherapy as indicated, and Quitline and SmokefreeTXT referrals

Who Is Running the Clinical Trial?

Dartmouth-Hitchcock Medical Center

Lead Sponsor

Trials

548

Recruited

2,545,000+